Abeona Therapeutics Inc (ABEO) was Reiterated by Maxim Group to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 14 from a previous price target of $8 . Maxim Group advised their investors in a research report released on Sep 29, 2016.
Abeona Therapeutics Inc closed down -0.5 points or -8.18% at $5.61 with 5,77,881 shares getting traded on Tuesday. Post opening the session at $6.18, the shares hit an intraday low of $5.46 and an intraday high of $6.18 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Sep 28, 2016, Todd Wider (director) purchased 5,000 shares at $5.48 per share price. According to the SEC, on Aug 3, 2015, Mark J Ahn (director) purchased 18,182 shares at $5.50 per share price.
Abeona Therapeutics Inc. develops and delivers gene therapy and plasma-based products for rare diseases. The Companys programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH) adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition the Company is also developing rare plasma protein therapies including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD using its SDF (Salt Diafiltration) ethanol-free process.